Zobrazeno 1 - 10
of 106
pro vyhledávání: '"FRANCESCO AMATI"'
Autor:
Francesco Blasi, Stefano Aliberti, Antonio Voza, Gabriele Bongiovanni, Antonio Tonutti, Anna Stainer, Mattia Nigro, Dean L Kellogg, Anoop Nambiar, Andrea Gramegna, Marco Mantero, Francesco Amati
Publikováno v:
BMJ Open Respiratory Research, Vol 11, Iss 1 (2024)
Objectives Vasoactive drugs have exhibited clinical efficacy in addressing pulmonary arterial hypertension, manifesting a significant reduction in morbidity and mortality. Pulmonary hypertension may complicate advanced interstitial lung disease (PH-I
Externí odkaz:
https://doaj.org/article/83888c04e1cb47bc9c942bccd30079d7
Autor:
Francesco Amati, Gloria Leonardi, Martina Contarini, Letizia Corinna Morlacchi, Anna Stainer, Giovanna Pizzamiglio, Stefano Aliberti, Francesco Blasi, Andrea Gramegna
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 18 (2024)
Background: Immunodeficiencies (IDs) are conditions caused by immune system dysfunctions which predispose to chronic infections. Cystic fibrosis (CF) patients are characterized by the presence of bronchiectasis filled with hyper-viscous secretions th
Externí odkaz:
https://doaj.org/article/ce5109ab043b49c894860986e6ef40cb
Autor:
Andrea Gramegna, Sofia Misuraca, Andrea Lombardi, Chiara Premuda, Ivan Barone, Margherita Ori, Francesco Amati, Mariangela Retucci, Erica Nazzari, Gianfranco Alicandro, Maurizio Ferrarese, Luigi Codecasa, Alessandra Bandera, Stefano Aliberti, Valeria Daccò, Francesco Blasi
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Introduction Over the last ten years an increasing prevalence and incidence of non-tuberculous mycobacteria (NTM) has been reported among patients with cystic fibrosis (CF) Viviani (J Cyst Fibros, 15(5):619–623, 2016). NTM pulmonary diseas
Externí odkaz:
https://doaj.org/article/fe48cd18824a4259bbdf06594649aec8
Autor:
Francesco Amati, Paolo Spagnolo, Christopher J. Ryerson, Justin M. Oldham, Andrea Gramegna, Anna Stainer, Marco Mantero, Nicola Sverzellati, Donato Lacedonia, Luca Richeldi, Francesco Blasi, Stefano Aliberti
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-15 (2023)
Abstract Interstitial lung diseases (ILDs) are complex and heterogeneous diseases. The use of traditional diagnostic classification in ILD can lead to suboptimal management, which is worsened by not considering the molecular pathways, biological comp
Externí odkaz:
https://doaj.org/article/6eb927b488fe4429ba7931fc39bb3650
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/2f2fdaae2ac84eea8f8de2eac7cc09c9
Autor:
Andrea Gramegna, Fabio Majo, Gianfranco Alicandro, Gloria Leonardi, Luca Cristiani, Francesco Amati, Martina Contarini, Stefano Aliberti, Alessandro Giovanni Fiocchi, Francesco Blasi
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-7 (2023)
Abstract Background The introduction of the novel therapy, Elexacaftor/Tezacaftor/Ivacaftor (ETI) has been effective in improving weight gain in both clinical trials and real-world studies. However, the magnitude of this effect appears to be heteroge
Externí odkaz:
https://doaj.org/article/61bc67b6a1e04543887d901b5e1473e4
Autor:
Francesco Amati, Francesco Bindo, Anna Stainer, Andrea Gramegna, Marco Mantero, Mattia Nigro, Linda Bussini, Michele Bartoletti, Francesco Blasi, Stefano Aliberti
Publikováno v:
Advances in Respiratory Medicine, Vol 91, Iss 3, Pp 224-238 (2023)
A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased
Externí odkaz:
https://doaj.org/article/c128a7d28ea94256ab9fe0af79d31bd2
Autor:
Francesco Amati, Anna Stainer, Giacomo Maruca, Maria De Santis, Giuseppe Mangiameli, Chiara Torrisi, Paola Bossi, Veronica Polelli, Francesco Blasi, Carlo Selmi, Giuseppe Marulli, Luca Balzarini, Luigi Maria Terracciano, Roberto Gatti, Stefano Aliberti
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 1047 (2024)
Different factors, not limited to the lung, influence the progression of ILDs. A “treatable trait” strategy was recently proposed for ILD patients as a precision model of care to improve outcomes. However, no data have been published so far on th
Externí odkaz:
https://doaj.org/article/a1fd10047e8b4301ab365327b0b47241
Autor:
Leonardo Terranova, Patrizia Risé, Andrea Gramegna, Christian Pinna, Carlo Agostoni, Marie-Louise Syrén, Stefano Turolo, Paola Marchisio, Francesco Amati, Stefano Aliberti, Angelo Sala, Francesco Blasi
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Bronchiectasis is characterized by neutrophilic inflammation and frequent exacerbations often associated with infections. Lipid mediators play critical roles in the inflammatory response, and the balance between anti-inflammatory
Externí odkaz:
https://doaj.org/article/d3fe04aa492f4387a56b9c5f7123ddb8
Autor:
Anna Stainer, Antonio Tonutti, Maria De Santis, Francesco Amati, Angela Ceribelli, Gabriele Bongiovanni, Chiara Torrisi, Antonio Iacopino, Giuseppe Mangiameli, Stefano Aliberti, Carlo Selmi
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovitis as the most common clinical manifestation, and interstitial lung disease (RA-ILD) represents one of the most common and potentially severe extra-articular f
Externí odkaz:
https://doaj.org/article/5ee93012a4fe4181ac2afa340c677dff